That last point matters: this is an industry-wide program run by the government, not a Lilly exclusive, so the read-through is shared with Novo
Additionally, hypoglycaemia (low blood sugar), though less common with GLP-1 agonists than with insulin or sulphonylureas, can cause irritability, confusion, and mood changes when it does occur, particularly in patients taking concurrent diabetes medications
The honest framing we give patients is this: the real cost of unregulated BPC-157 is not the price, it is injecting something whose concentration and purity you cannot verify
Products marketed as for research only are a red flag for personal medical use unless they are part of a legitimate research study through a legitimate research institute
doi:10.3945/ajcn.2010.29885